Literature DB >> 7688433

Natural history of prostatism: urinary flow rates in a community-based study.

C J Girman1, L A Panser, C G Chute, J E Oesterling, D M Barrett, C C Chen, H M Arrighi, H A Guess, M M Lieber.   

Abstract

Urinary flow rates were measured in a randomly selected community sample of more than 2,000 men 40 to 79 years old with no history of prostate surgery, prostate cancer or certain other diseases known to interfere with normal voiding. Peak urinary flow rates decreased from a median of 20.3 ml. per second in men 40 to 44 years old to 11.5 ml. per second for men 75 to 79 years old, while voided volumes decreased from a median of 355.5 to 222.5 ml. for the same age ranges. Peak flow rates of less than 10 ml. per second were found in 6% of the men aged 40 to 44 years, increasing to 35% among men aged 75 to 79 years. Urological standards for peak urinary flow rate should be based on community data, and should account for age and voided volume. Our study may serve as the starting point for the development of community-based flow rate normal ranges. Nomograms are given to permit estimating flow rate percentiles as a function of age and voided volume.

Entities:  

Mesh:

Year:  1993        PMID: 7688433     DOI: 10.1016/s0022-5347(17)35640-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

Review 1.  Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life.

Authors:  Donald MacDonald; Thomas A McNicholas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options.

Authors:  Jaspreet S Sandhu; E Darracott Vaughan
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Underdetection of clinical benign prostatic hyperplasia in a general medical practice.

Authors:  M F Collins; R H Friedman; A Ash; R Hall; M A Moskowitz
Journal:  J Gen Intern Med       Date:  1996-09       Impact factor: 5.128

Review 4.  Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease.

Authors:  Leonard S Marks
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

5.  Interpretation of quality-of-life scores.

Authors:  Mary-Margaret Chren
Journal:  J Invest Dermatol       Date:  2010-05       Impact factor: 8.551

Review 6.  Interpretation of quality of life changes.

Authors:  E Lydick; R S Epstein
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

Review 7.  Management of non-complicated BPH: proposition of a renewed decision tree.

Authors:  Francois Desgrandchamps; Alexandre de la Taille; Abdel-Rahmène Azzouzi; Marc Fourmarier; Olivier Haillot; Bertrand Lukacs; Christian Saussine
Journal:  World J Urol       Date:  2006-06-21       Impact factor: 4.226

8.  The prevalence of lower urinary tract symptoms in Austrian males and associations with sociodemographic variables.

Authors:  G Haidinger; S Madersbacher; T Waldhoer; G Lunglmayr; C Vutuc
Journal:  Eur J Epidemiol       Date:  1999-09       Impact factor: 8.082

Review 9.  Predictive medicine in non-malignant urological disorders.

Authors:  Mariangela Mancini; Antonio Cisternino; Ivan Matteo Tavolini; Fabrizio Dal Moro; Pierfrancesco Bassi
Journal:  World J Urol       Date:  2003-12-20       Impact factor: 4.226

10.  Therapeutic options in the treatment of benign prostatic hyperplasia.

Authors:  Jaspreet S Sandhu
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.